Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent
1975-09-09
1977-02-22
Meyers, Albert T.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reduced antigenicity, reduced ability to bind complement, or...
260112R, 260112B, 260113, 260121, 424 88, 424287, A61K 3702, A61K 3714, C07G 704
Patent
active
040092674
ABSTRACT:
Orgotein cross-linked with itself or with non-antigenic injectable serum or tissue protein has a substantially longer half-life in the blood after injection than orgotein.
REFERENCES:
patent: 3687927 (1972-08-01), Huber
patent: 3758682 (1973-09-01), Huber
patent: 3813289 (1974-05-01), Huber
Lenard, Chem. Abs. vol. 68, 1968 No. 92962v.
Niehaus, Chem. Abs. vol. 72, 1970, No. 108777j.
Huber Wolfgang
Saifer Mark G.
Williams Lewis D.
Diagnostic Data, Inc.
Fagelson A. P.
Meyers Albert T.
LandOfFree
Cross-linked orgotein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cross-linked orgotein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cross-linked orgotein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-324418